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Supplementary Fig. 1: Titre- and time-dependent SARS-CoV-2 infection of hESC-derived 
cardiomyocytes. Representative fluorescent images (n=2 independent experiments) of human 
embryonic stem cell-derived cardiomyocytes (hESC-CMs) infected with SARS-CoV-2 at several 
different viral titres ((0.001-0.1 multiplicity of infection (MOI)), or left untreated, and incubated for 
different time periods (24-72 h). Infected cells were immunolabelled after fixation with 2% formaldehyde 
and permeabilization with BD Perm/Wash buffer (BD Biosciences, 554723) using sheep anti-SARS-
CoV-2 nucleocapsid antibody (DA114, MRC-PPU). Cells were visualised using a donkey anti-sheep 





































Supplementary Fig. 2: Cell populations of pure, beating cardiomyocytes. a-e Representative 
brightfield video files of beating human embryonic stem cell-derived cardiomyocytes (hESC-CMs) 
following infection with 25 μL (a), 50 μL (b), or 100 μL (c) SARS-CoV-2 spike pseudotyped lentivirus. 
Control cells were treated with 100 μL vesicular stomatitis virus (VSV-G) pseudotyped lentivirus (d) or 
left untreated with viral particles (e). f-i hESC purity flow cytometry data. f Cells were gated using FSC 
and SSC. g Single cells were distinguished from doublets and aggregates by plotting FSC-A against 
FSC-W. Subsequent histograms were gated on the single cells population. h The Troponin-T gate was 
determined using cells stained with IgG control. i Representative plot displaying purity of hESC-CM 
differentiation by flow cytometry using an antibody specific for cardiac troponin-T (96.8 % of the 








Supplementary Table. 1: Compounds used, their protein targets, and other relevant information. 
The table shows the compounds used in screening experiments at the denoted concentrations, and 
their respective protein targets shown to be expressed in the human embryonic stem cell-derived 
cardiomyocytes (hESC-CMs) cell model, as well as adult cardiomyocytes. Concentrations used in the 
hESC-CM screen were chosen based on the pIC50 values reported in literature or on IUPHAR/BPS 
Guide to PHARMACOLOGY (https://www.guidetopharmacology.org). 
